51. Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response
- Author
-
Gulcin Tezcan, Oznur Yildirim, Berrin Tunca, Isil Ezgi Eryilmaz, Unal Egeli, Necdet Karli, Ozlem Taskapilioglu, Gulsah Cecener, Gülfer Atasayar, Mehmet Zarifoglu, Secil Ak, Fatma Ezgi Can, Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı., Atasayar, Gülfer, Eryılmaz, Işıl Ezgi, Karlı, Necdet, Egeli, Ünal, Zarifoğlu, Mehmet, Çeçener, Gülşah, Taşkapılıoğlu, Özlem, Tunca, Berrin, Yıldırım, Öznur, Ak, Seçil, Tezcan, Gülçin, Can, Fatma Ezgi, ABI-6078-2020, AAP-9988-2020, AAH-1656-2021, GWV-3548-2022, AAH-3843-2020, F-8554-2017, and AAH-1420-2021
- Subjects
Male ,Central nervous system agents ,Genetic association studies ,Genomic DNA ,Pharmacology ,ABCB1 protein, human ,Treatment response ,030226 pharmacology & pharmacy ,0302 clinical medicine ,P-glycoproteins ,Valproic acid ,Medicine ,Amitriptyline ,Treatment outcome ,2D6 ,Priority journal ,Valproic Acid ,Analogs and derivatives ,CYP2C19 protein, human ,Prophylactic therapy response ,2C19 ,Propranolol ,Phenotype ,Neurology ,Cytochrome P-450 CYP2D6 ,Migraine with aura ,Clinical neurology ,Migraine without aura ,Migraine disorders ,Female ,medicine.drug ,Human ,Topiramate ,Adult ,CYP2D6 ,ATP Binding Cassette Transporter, Subfamily B ,Genotype ,MDR1 ,Multidrug-resistance ,CYP2C19 ,Fructose ,Major clinical study ,Polymorphism, genetic ,Neurosciences & neurology ,Article ,03 medical and health sciences ,Drug Resistant Epilepsy ,Epilepsy ,Carbamazepine ,Cytochrome P450 2C19 ,Multidrug resistance protein 1 ,Genetics ,Humans ,Migraine treatment ,Polymorphism ,Migraine ,Alleles ,Aged ,Genetic association study ,Cytochrome-P450 ,C3435t polymorphism ,Genetic polymorphism ,business.industry ,Prophylaxis ,Neurosciences ,Multidrug resistance protein ,Frequency ,Cytochrome P450 2D6 ,medicine.disease ,Monotherapy ,Gene frequency ,Cytochrome P-450 CYP2C19 ,Risk factors ,Pharmacogenetics ,DNA polymorphism ,Drug resistance ,Genetic association ,Neurology (clinical) ,Risk factor ,business ,030217 neurology & neurosurgery - Abstract
Prophylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes ( p =0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine ( β 2 =1.152, p =0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1 , CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients.
- Published
- 2016